IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck

Trial Success:
IO Biotech's Phase 2 basket trial (IOB-022/KN-D38) evaluating IO102-IO103 in combination with Keytruda (pembrolizumab) achieved its primary endpoint with a confirmed overall response rate (ORR) of 44.4% in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20.

Progression-Free Survival:
The trial showed an encouraging median progression-free survival (PFS) of 6.6 months, with more than half of the patients experiencing over 180 days of progression-free survival.

Disease Control Rate:
The combination therapy demonstrated a 66.7% disease control rate (DCR) in the SCCHN cohort.

Safety Profile:
The safety profile was consistent with previously reported data when combined with anti-PD-1 monotherapy, with no new safety concerns identified.

Clinical Trials:
IO Biotech is conducting several clinical trials, including a pivotal Phase 3 trial (IOB-013/KN-D18) in advanced melanoma and additional Phase 2 basket trials exploring IO102-IO103 in different treatment contexts for solid tumors.

Collaboration:
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which supplies pembrolizumab. IO Biotech retains global commercial rights to IO102-IO103.